Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus

In Press, (this is not the final "Version of Record"). Available online 25 January, 2024
Author(s): Nikita Sharma, Debashree Debasish Das and Pooja A. Chawla*
Published on: 25 January, 2024

Article ID: e250124226249

DOI: 10.2174/0115733998261825231026060241

Price: $95

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease caused by CD4+ and CD8+ that are activated via CD3+ cells and finally lead to the macrophages destroying the beta cells in the pancreas thereby causing diabetes. The anti-CD3 humanized monoclonal antibody was approved on 17th November 2022 by the United States Food Drug Administration (USFDA) with the name teplizumab and the brand name TZIELD. This is the only approved drug that treats type 1 diabetes (T1D) by delaying the onset of stage 3 in type 1 diabetes (T1D). This review outlines essential features of teplizumab including its brief introduction to its mechanism and other therapies for the treatment and various risks as well as the pharmacokinetics and pharmacodynamics of this disease and the clinical trial reports for the completed and ongoing therapies.

[1]
Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1)(Suppl. 1): S62-9.
[http://dx.doi.org/10.2337/dc10-S062] [PMID: 20042775]
[2]
Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers 2017; 3(1): 17016.
[http://dx.doi.org/10.1038/nrdp.2017.16] [PMID: 28358037]
[3]
Gillespie KM. Type 1 diabetes: Pathogenesis and prevention. CMAJ 2006; 175(2): 165-70.
[http://dx.doi.org/10.1503/cmaj.060244] [PMID: 16847277]
[4]
Rapini N, Schiaffini R, Fierabracci A. Immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: An overview. Int J Mol Sci 2020; 21(6): 2103.
[http://dx.doi.org/10.3390/ijms21062103] [PMID: 32204344]
[5]
Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: Recent developments. BMJ 2004; 328(7442): 750-4.
[http://dx.doi.org/10.1136/bmj.328.7442.750] [PMID: 15044291]
[6]
Giwa AM, Ahmed R, Omidian Z, et al. Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment. World J Diabetes 2020; 11(1): 13-25.
[http://dx.doi.org/10.4239/wjd.v11.i1.13] [PMID: 31938470]
[7]
Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: Autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne) 2017; 8: 343.
[http://dx.doi.org/10.3389/fendo.2017.00343] [PMID: 29259578]
[8]
Rathod S. Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes. Diabetology 2022; 3(1): 79-96.
[http://dx.doi.org/10.3390/diabetology3010007]
[9]
von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and future therapies for type 1 diabetes. Diabetologia 2021; 64(5): 1037-48.
[http://dx.doi.org/10.1007/s00125-021-05398-3] [PMID: 33595677]
[10]
Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013; 1(4): 306-16.
[http://dx.doi.org/10.1016/S2213-8587(13)70065-2] [PMID: 24622416]
[11]
Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment. Diabetes Care 2014; 37(4): 1069-75.
[http://dx.doi.org/10.2337/dc13-0604] [PMID: 24296850]
[12]
Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015; 125(8): 3285-96.
[http://dx.doi.org/10.1172/JCI81722] [PMID: 26193635]
[13]
Bender C, Rodriguez-Calvo T, Amirian N, Coppieters KT, von Herrath MG. The healthy exocrine pancreas contains preproinsulin-specific CD8 T-cells that attack islets in type 1 diabetes. Sci Adv 2020; 6(42): eabc5586.
[http://dx.doi.org/10.1126/sciadv.abc5586] [PMID: 33067232]
[14]
Foroutan N, Hopkins RB, Tarride JE, Florez ID, Levine M. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis. Clin Invest Med 2019; 42(1): E53-65.
[http://dx.doi.org/10.25011/cim.v42i1.32393] [PMID: 30904037]
[15]
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer 2014; 14(2): 135-46.
[http://dx.doi.org/10.1038/nrc3670] [PMID: 24457417]
[16]
Speake C, Greenbaum CJ. Approval of teplizumab: Implications for patients. Nat Rev Endocrinol 2023; 19(7): 377-8.
[http://dx.doi.org/10.1038/s41574-023-00849-w] [PMID: 37202589]
[17]
Hirsch JS. FDA approves teplizumab: A milestone in type 1 diabetes. Lancet Diabetes Endocrinol 2022.
[PMID: 36436528]
[18]
Christensen J, Goodman B. FDA approves first treatment to delay onset of type 1 diabetes CNN. 2022. Available From: https://edition.cnn.com/2022/11/17/health/tzield-teplizumab-diabetic-treatment/index.html
[19]
Leon F. Methods and compositions for preventing type 1 diabetes. US11434291B2 2022.
[20]
Provention Bio. Teplizumab for the delay of progression to clinical stage 3 type 1 diabetes in at-risk patients. 2021. Available From: https://www.fda.gov/media/149389/download
[21]
Gaglia J, Kissler S. Anti-CD3 antibody for the prevention of type 1 diabetes: A story of perseverance. Biochemistry 2019; 58(40): 4107-11.
[http://dx.doi.org/10.1021/acs.biochem.9b00707] [PMID: 31523950]
[22]
Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13(583): eabc8980.
[http://dx.doi.org/10.1126/scitranslmed.abc8980] [PMID: 33658358]
[23]
Smigoc Schweiger D. Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr 2022; 96(6): 1-15.
[http://dx.doi.org/10.1159/000524866] [PMID: 35533645]
[24]
Provention Bio Teplizumab Prescribing information. TZIELD™ (teplizumab-mzwv) injection, for intravenous use. 2022. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf
[25]
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381(7): 603-13.
[http://dx.doi.org/10.1056/NEJMoa1902226] [PMID: 31180194]
[26]
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38(10): 1964-74.
[http://dx.doi.org/10.2337/dc15-1419] [PMID: 26404926]
[27]
Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61(8): 2066-73.
[http://dx.doi.org/10.2337/db11-1538] [PMID: 22688329]
[28]
Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: A consensus report. Diabetes Care 2015; 38(10): 1975-85.
[http://dx.doi.org/10.2337/dc15-1429] [PMID: 26404927]
[29]
Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62(11): 3766-74.
[http://dx.doi.org/10.2337/db13-0345] [PMID: 23835333]
[30]
Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378(9790): 487-97.
[http://dx.doi.org/10.1016/S0140-6736(11)60931-8] [PMID: 21719095]
[31]
Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 2019; 7(1): 52-64.
[http://dx.doi.org/10.1016/S2213-8587(18)30112-8] [PMID: 30528099]
[32]
Herold KC, Vignali DAA, Cooke A, Bluestone JA. Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013; 13(4): 243-56.
[http://dx.doi.org/10.1038/nri3422] [PMID: 23524461]
[33]
Nourelden AZ, Elshanbary AA, El-Sherif L, et al. Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: A systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 2021; 21(10): 1895-904.
[http://dx.doi.org/10.2174/1871530320999201209222921] [PMID: 33302842]
[34]
Zheng P, Li Z, Zhou Z. Gut microbiome in type 1 diabetes: A comprehensive review. Diabetes Metab Res Rev 2018; 34(7): e3043.
[http://dx.doi.org/10.1002/dmrr.3043] [PMID: 29929213]
[35]
Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 2012; 4(118): 118ra12.
[http://dx.doi.org/10.1126/scitranslmed.3003401]
[36]
Yu H, Gagliani N, Ishigame H, et al. Intestinal type 1 regulatory T-cells migrate to periphery to suppress diabetogenic T-cells and prevent diabetes development. Proc Natl Acad Sci USA 2017; 114(39): 10443-8.
[http://dx.doi.org/10.1073/pnas.1705599114] [PMID: 28894001]
[37]
Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, fc receptor nonbinding okt3 antibody, huOKT3??1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68(5): 608-16.
[http://dx.doi.org/10.1097/00007890-199909150-00003] [PMID: 10507477]
[38]
Hering J. Insulin independence after single-donor islet transplantation in type 1 diabetes with hOKT3γ-1 (ala-ala), sirolimus, and tacrolimus therapy. Am J Transplant 2001; 1: 180.
[39]
Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4(3): 390-401.
[http://dx.doi.org/10.1046/j.1600-6143.2003.00351.x] [PMID: 14961992]
[40]
Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci 2008; 1150(1): 14-24.
[http://dx.doi.org/10.1196/annals.1447.054] [PMID: 19120262]
[41]
Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J Rheumatol 2002; 29(9): 1907-13.
[PMID: 12233885]
[42]
Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: Clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2019; 62(4): 655-64.
[http://dx.doi.org/10.1007/s00125-018-4786-9] [PMID: 30569273]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy